Highly activated and expanded natural killer cells for
- Slides: 7
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy by Tarun K. Garg, Susann M. Szmania, Junaid A. Khan, Antje Hoering, Paul A. Malbrough, Amberly Moreno-Bost, Amy D. Greenway, Joshuah D. Lingo, Xin Li, Shmuel Yaccoby, Larry J. Suva, Brian Storrie, Guido Tricot, Dario Campana, John D. Shaughnessy, Bijay P. Nair, William T. Bellamy, Joshua Epstein, Bart Barlogie, and Frits van Rhee haematol Volume 97(9): 1348 -1356 September 5, 2012 © 2012 by Ferrata Storti Foundation
Exp-NK cells have an activated phenotype. Tarun K. Garg et al. Haematologica 2012; 97: 1348 -1356 © 2012 by Ferrata Storti Foundation
Exp-NK cells (unselected, purity >92%) kill MM cells and this killing is mediated by the perforin pathway and critical activating receptor-ligand interactions. Tarun K. Garg et al. Haematologica 2012; 97: 1348 -1356 © 2012 by Ferrata Storti Foundation
Human exp-NK cells significantly inhibit luciferase-transfected OPM 2 myeloma tumor growth in the NOD/scid/IL 2 Rγnull-hu model. Tarun K. Garg et al. Haematologica 2012; 97: 1348 -1356 © 2012 by Ferrata Storti Foundation
Exp-NK cell treatment protects bone from myeloma-induced osteolysis. Tarun K. Garg et al. Haematologica 2012; 97: 1348 -1356 © 2012 by Ferrata Storti Foundation
Exp-NK cells inhibit primary MM cell growth in a NOD/scid/IL 2 Rγnull-hu model. Tarun K. Garg et al. Haematologica 2012; 97: 1348 -1356 © 2012 by Ferrata Storti Foundation
Human exp-NK cells persist for up to 28 days, proliferate further in the peripheral blood of OPM 2 myeloma-bearing NOD/scid/IL 2 Rγnull mice and can be detected in the MM tumor bed. Tarun K. Garg et al. Haematologica 2012; 97: 1348 -1356 © 2012 by Ferrata Storti Foundation